Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy

Conditions:   NSCLC Stage IV;   NSCLC Stage IIIB Intervention:   Drug: Ipatasertib Sponsors:   University of Kansas Medical Center;   University of Iowa;   University of Kentucky Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials